Fyremadel Shortage Update: What Patients Need to Know in 2026

If you've been prescribed Fyremadel (ganirelix acetate) as part of your IVF cycle and struggled to fill the prescription, you're not imagining it. Many fertility patients across the United States are running into the same problem in 2026. Here's what's actually happening with the Fyremadel supply — and what it means for you.

Is Fyremadel Officially in Shortage in 2026?

No — not officially. As of early 2026, Fyremadel (ganirelix acetate) is not listed on the FDA Drug Shortage Database or the ASHP (American Society of Health-System Pharmacists) Current Drug Shortages list. There is no formal, government-declared nationwide shortage.

However, "not formally in shortage" and "easy to find at your local pharmacy" are two very different things. Real-world reports from fertility patients and clinics consistently indicate that Fyremadel can be difficult to locate at standard retail pharmacies — and availability varies significantly by region.

A Brief History of Fyremadel Supply Issues

Ganirelix acetate was first approved by the FDA in 1999 under the brand name Antagon, made by Organon. Over the years the medication landscape has shifted:

• 1999: FDA approved Antagon (ganirelix acetate) for inhibition of premature LH surges during controlled ovarian hyperstimulation
• Generic entry: Amphastar Pharmaceuticals and other manufacturers introduced generic ganirelix acetate, improving supply diversity
• Fyremadel launch: Ferring Pharmaceuticals launched Fyremadel as a new branded version of ganirelix acetate, manufactured by Sun Pharmaceutical Industries
• 2023-2025: Periodic supply constraints reported, particularly at retail chain pharmacies, driven by limited manufacturer base and growing IVF demand
• 2026: No formal shortage, but availability remains inconsistent at non-specialty pharmacies

Why Is Fyremadel Still Hard to Find Without a Formal Shortage?

Several structural factors contribute to ongoing availability challenges:

• Limited manufacturers: Primarily Ferring Pharmaceuticals (Fyremadel) and Amphastar (generic). Few companies means limited redundancy if one manufacturer has a disruption.
• Specialty-only distribution: Most retail chain pharmacies (CVS, Walgreens, Rite Aid) do not routinely stock fertility injectables. Specialty pharmacies maintain better inventory but may have regional limitations.
• Rising IVF demand: Over 400,000 ART cycles are performed annually in the US, a number that continues to grow. Demand for IVF medications is outpacing the speed of supply chain expansion.

What Should You Do If Fyremadel Is Unavailable?

If your pharmacy doesn't have Fyremadel, take these steps immediately:

1. Use medfinder: medfinder.com calls pharmacies near you to identify which ones can fill your prescription. This is the fastest way to get real availability information.
2. Contact your fertility clinic: Your IVF coordinator may have direct access to a specialty pharmacy with stock.
3. Ask about generic ganirelix: Generic ganirelix acetate (Amphastar) is bioequivalent to Fyremadel and may be available when the brand is not.
4. Ask about Cetrorelix: Your doctor can switch you to Cetrorelix (Cetrotide), a clinically equivalent GnRH antagonist, in most cases. Read our full Fyremadel alternatives guide for details.

Is the Fyremadel Supply Expected to Improve?

The outlook is cautiously optimistic. Generic ganirelix availability from Amphastar Pharmaceuticals provides some supply diversity. More specialty pharmacies are entering the fertility medication space. However, as long as the manufacturer base remains limited and IVF demand continues to grow, patients should plan ahead and not wait until the day they need Fyremadel to start looking.

For a deeper look at the root causes of Fyremadel availability challenges, see our article Why Is Fyremadel So Hard to Find? [Explained for 2026].